Skip to content
Research/Nad Protocols/NAD+

NAD+

compound

moderate evidencePublic

NAD+ (Nicotinamide Adenine Dinucleotide) is a crucial coenzyme found in all living cells that plays a key role in energy metabolism and mitochondrial function. It is essential for the conversion of nutrients into energy and supports cellular repair processes, making it important for longevity and health optimization. Although there are no clinical trials directly on NAD+, its significance is well-supported by extensive research on its role in cellular health.

Category: Nad ProtocolsUpdated 7/14/2026

Intelligence Profile

Overview

Overview of NAD+

NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme found in every living cell that plays a fundamental role in cellular energy production and metabolism. This molecule serves as an essential cofactor in cellular respiration, helping convert nutrients into energy while also supporting numerous other vital cellular processes including DNA repair, gene expression regulation, and cellular stress responses. NAD+ levels naturally decline with age, which has sparked significant scientific interest in understanding its role in aging and age-related diseases.

The importance of NAD+ for longevity and health optimization stems from its central involvement in cellular maintenance and repair mechanisms. Current research suggests NAD+ influences key pathways associated with aging, including sirtuin proteins that regulate cellular stress responses and mitochondrial function. Studies are investigating connections between NAD+ metabolism and neurodegenerative conditions like Alzheimer's disease, as well as cardiovascular health and metabolic disorders. Clinical trials are examining NAD+ precursors like nicotinamide riboside in conditions ranging from heart failure to Parkinson's disease, though evidence for anti-aging benefits in healthy individuals remains limited.

While NAD+ supplementation has gained attention as a potential longevity intervention, the clinical evidence is still developing. Most human studies to date have focused on specific disease conditions rather than general health optimization in healthy aging adults. The research landscape continues to evolve as scientists work to better understand how NAD+ metabolism affects human health and whether supplementation strategies can meaningfully impact aging processes.

This information is for educational purposes only and should not replace professional medical advice. Consult healthcare providers before starting any supplementation regimen.

Biohacker actions
Check interactionsView protocols

Deep dive

Intelligence Profile

AI-EnrichedUpdated Jul 14, 2026

The Science

Mechanism of Action

NAD+ (nicotinamide adenine dinucleotide) functions through multiple interconnected molecular pathways that are fundamental to cellular metabolism and energy production.

Core Metabolic Function
At the cellular level, NAD+ serves as a critical coenzyme in energy metabolism, facilitating the transfer of electrons in redox reactions essential for ATP production. The compound acts as an electron acceptor in glycolysis and the citric acid cycle, making it indispensable for cellular respiration and energy generation.

Sirtuin Pathway Activation
NAD+ functions as an essential cofactor for sirtuin proteins, a family of NAD+-dependent deacetylases. Evidence shows that NAD+ metabolism is directly linked to sirtuin network function, which regulates mitochondrial function and metabolic homeostasis. This connection appears particularly relevant in metabolic disorders, as suggested by research examining the sirtuin network's role in diabetes and metabolism.

Mitochondrial Function
The compound plays a crucial role in maintaining mitochondrial health and function. Through its involvement in the sirtuin network, NAD+ helps regulate mitochondrial biogenesis and cellular energy production. This mechanism may be particularly important in age-related conditions where mitochondrial dysfunction contributes to disease progression.

PARP-Mediated Cellular Responses
NAD+ also serves as a substrate for poly(ADP-ribose) polymerases (PARPs), enzymes involved in DNA repair and cellular stress responses. Research indicates that PARP1 activity, which consumes NAD+, can influence cellular injury responses through interactions with sirtuins like SIRT6.

Clinical Evidence Limitations
While several clinical trials have investigated NAD+ precursors like nicotinamide riboside in conditions including heart failure and neurodegenerative diseases, the mechanistic evidence in humans remains limited. Most molecular pathway data comes from preclinical studies, and more research is needed to fully establish the therapeutic mechanisms in human disease.

This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering NAD+ supplementation.

Clinical Applications

NAD+ and its precursors are being investigated for several clinical conditions, though research remains in early stages with limited completed trials.

Cardiovascular Disease

NAD+ precursors have been studied in heart failure. One completed Phase 1/2 trial (NCT03423342) examined nicotinamide riboside supplementation in patients with systolic heart failure, though specific results from this study are not yet available in the provided evidence.

Neurodegenerative Disorders

NAD+ is being actively investigated for neurodegenerative conditions, particularly Parkinson's disease variants. The NADAPT Study (NCT06162013) is an ongoing Phase 2 randomized, double-blind trial testing NAD replenishment therapy specifically for atypical Parkinsonism. This represents one of the more advanced clinical investigations into NAD+'s therapeutic potential for neurological conditions.

The research literature suggests NAD+ may be relevant to Alzheimer's disease through metabolic pathways, with studies examining connections between NAD+ metabolism, mitochondrial function, and tau protein modifications. However, these appear to be mechanistic studies rather than completed clinical trials.

Exercise and Athletic Performance

At least one completed trial (NCT04907110) has examined NAD+ precursor supplementation in combination with exercise, though specific outcomes are not detailed in the available evidence.

Current Clinical Evidence Limitations

The clinical evidence for NAD+ supplementation remains limited. While multiple trials are listed, many have unknown status or lack published results. The mechanistic research suggests potential applications in aging, metabolic disorders, and neurodegenerative diseases, but translation to proven clinical benefits requires more robust trial data.

This information is for educational purposes only and should not be considered personalized medical advice. Consult with healthcare providers before starting any supplementation regimen.

Safety Profile

The safety evidence for NAD+ supplementation is extremely limited based on the provided research. Most evidence focuses on metabolic mechanisms rather than clinical safety data, making it impossible to provide a comprehensive safety assessment.

Available Clinical Trial Safety Data

The evidence includes only a few completed clinical trials:

  • One Phase 1/2 trial of nicotinamide riboside (an NAD+ precursor) in systolic heart failure patients (NCT03423342) - no safety outcomes reported in provided data
  • One completed trial examining NAD+ supplementation with exercise (NCT04907110) - no safety data provided

Critical Evidence Gaps

No safety data is available from the provided evidence regarding:

  • Common or rare side effects
  • Serious adverse events
  • Drug interactions
  • Contraindications
  • Dosing-related safety concerns
  • Long-term safety profile

Populations of Potential Concern

While specific safety data is lacking, the provided research suggests NAD+ affects fundamental cellular processes including:

  • Mitochondrial function
  • Metabolic pathways
  • Circadian rhythms
  • Immune system function

Without adequate safety data, particular caution may be warranted in:

  • Pregnant or breastfeeding women
  • Children and adolescents
  • Patients with metabolic disorders
  • Individuals taking medications that affect cellular metabolism

Current Research Status

One Phase 2 trial for atypical Parkinsonism is currently recruiting (NCT06162013), but safety results are not yet available.

Important Disclaimer

The evidence provided contains insufficient safety data to adequately assess the risk profile of NAD+ supplementation. Anyone considering NAD+ supplementation should consult with a healthcare provider, as this analysis cannot provide personalized medical advice or substitute for professional medical evaluation.

The lack of comprehensive safety data in the provided evidence represents a significant limitation in assessing the clinical safety of NAD+ supplementation.

Key Research Papers

Key Research Papers and Clinical Trials

Current research on NAD+ spans multiple therapeutic areas, though much of the evidence comes from preclinical studies and small clinical trials.

Neurological and Aging Research

Recent research has focused heavily on NAD+'s role in neurodegeneration and aging. Several 2026 review papers examine NAD+ metabolism in the context of Alzheimer's disease, exploring connections between bioenergetic impairment, tau protein modifications, and metabolic dysfunction in brain cells. These papers discuss theoretical mechanisms linking NAD+-dependent processes to neuronal energy networks, though they appear to be review articles rather than original experimental studies.

The sirtuin network, which depends on NAD+ as a cofactor, has been identified as a key connection between NAD+ metabolism, mitochondrial function, and metabolic balance. Research has also explored NAD+-related pathways in other age-related conditions, with one study examining ergothioneine's effects on circadian rhythms and another reviewing connections between virtual environments and NAD+ in healthy aging contexts.

Clinical Trial Evidence

The clinical trial landscape for NAD+ research shows mixed progress:

  • Heart Failure: A completed Phase 1/2 trial (NCT03423342) investigated nicotinamide riboside, an NAD+ precursor, in patients with systolic heart failure. Results from this study have not been detailed in the provided evidence.

  • Exercise and Supplementation: One completed trial (NCT04907110) examined NAD+ precursor supplementation combined with exercise, though specific outcomes are not available in the current evidence.

  • Parkinson's Disease: An ongoing Phase 2 trial (NCT06162013) called the NADAPT Study is currently recruiting participants to test NAD+ replenishment therapy for atypical Parkinsonism. This randomized, double-blind trial represents one of the more advanced clinical investigations of NAD+ therapy.

Research Limitations

The evidence base shows significant gaps. Many of the recent papers appear to be reviews or mechanistic studies rather than controlled clinical trials. Sample sizes and specific study designs for the completed trials are not provided in the available evidence. The field appears to be in early stages, with more theoretical and preclinical work than robust human clinical data.

This synthesis is based on limited evidence summaries. Individuals considering NAD+ supplementation should consult healthcare providers for personalized medical advice.

Clinical Protocols

Protocols

The literature on NAD+ supplementation protocols is limited, with most clinical evidence focusing on NAD+ precursors rather than direct NAD+ administration. The available evidence shows significant variation in dosing approaches.

NAD+ Precursor Protocols

Nicotinamide Riboside (NR)
Clinical trials have investigated NR as an NAD+ precursor, though specific dosing details from the completed studies (NCT03423342 for systolic heart failure and NCT04907110 for exercise supplementation) are not detailed in the available evidence. One ongoing phase 2 trial (NCT06162013) is examining NAD+ replenishment therapy for atypical Parkinsonism, but dosing protocols have not been reported.

General Considerations
The mechanistic literature suggests NAD+ plays roles in metabolic homeostasis, mitochondrial function, and cellular energy networks through sirtuins and other NAD+-dependent enzymes. However, the optimal dosing strategies for therapeutic applications remain under investigation.

Route of Administration

The available evidence does not provide clear details on preferred routes of administration (oral, intravenous, etc.) or standardized dosing schedules for NAD+ or its precursors in clinical settings.

Evidence Limitations

The current literature lacks comprehensive, well-documented protocols for NAD+ supplementation. Most studies focus on mechanistic understanding rather than clinical dosing guidelines. The ongoing clinical trials may provide more definitive protocol guidance once completed.

Medical Disclaimer: This information is for educational purposes only and is not personalized medical advice. Any NAD+ supplementation should only be undertaken under appropriate medical supervision. Consult with a healthcare provider before beginning any NAD+ or precursor supplementation regimen.

Outcomes & Evidence

Outcomes

The evidence for measurable clinical outcomes from NAD+ supplementation is limited, with most available data coming from early-phase trials and mechanistic studies rather than robust clinical endpoints.

Cardiovascular Outcomes

One completed phase 1/2 trial (NCT03423342) investigated nicotinamide riboside, an NAD+ precursor, in patients with systolic heart failure. However, specific outcome measures and results from this study are not detailed in the available evidence.

Exercise and Metabolic Outcomes

A completed trial (NCT04907110) examined NAD+ precursor supplementation combined with exercise, but measurable results are not provided in the current evidence base.

Neurological Outcomes

An ongoing phase 2 trial (NCT06162013) is investigating NAD+ replenishment therapy for atypical Parkinsonism, but results are not yet available as the study is still recruiting participants.

Mechanistic Biomarkers

The available literature primarily focuses on mechanistic pathways rather than clinical outcomes. Studies discuss NAD+ metabolism's role in:

  • Mitochondrial function regulation
  • Sirtuin network activation
  • Metabolic homeostasis
  • Circadian rhythm regulation

However, specific biomarker changes, symptom improvements, or other measurable clinical endpoints are not reported in the provided evidence.

Evidence Limitations

The strength of evidence for clinical outcomes remains weak. While multiple studies explore NAD+ metabolism's theoretical benefits across various conditions including Alzheimer's disease, pulmonary fibrosis, and aging-related decline, the available evidence lacks concrete clinical outcome data from completed trials.

This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering NAD+ supplementation.